KFU. Card publication. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

MUSASHI 2 (MSI2) EXPRESSION AS AN INDEPENDENT PROGNOSTIC BIOMARKER IN NON-SMALL CELL LUNG CANCER (NSCLC)

Form of presentation

Articles in international journals and collections

Year of publication

2021

��

��

Authors, employees of KFU

Bumber Yanis Alekseevich, author

Deneka Aleksandr Yaroslavovich, author

Serebriyskiy Ilya Genrikhovich, author

Tikhomirova Mariya Vladimirovna, author

Topchu Yuliya Alekseevna, author

Yugay Veronika Nikolaevna, author

Other authors

Ratner Ekaterina Yurevna, author

Authors, postgraduates KFU

Mazitova Aleksandra Maratovna, postgraduate kfu

Bibliographic description in the original language

Deneka A. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) /A. Deneka, I.Topchu, N. Karnaukhov, A. Mazitova, V. Yugai, M. Voloshin, M. Tikhomirova, O. Kit, E. Frantsiyants , L.Kharin, T. Airapetova, E. Ratner, Al. Sabirov, Z. Abramova, I. Serebriiskii, Y. Boumber // Journal of Thoracic Disease.-2021.- V.13,N.3.- R. 1370-1379 DOI: 10.1039/d0ra10610k (Q2 SJE 0.572 IF 2.046)

Annotation

Background: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). Methods: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received tandard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). Results: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. Conclusions: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted

Keywords

Non-small cell lung cancer (NSCLC), overall survival (OS), RNA binding proteins, Musashi-2 (MSI2), prediction biomarkers

The name of the journal

JOURNAL OF THORACIC DISEASE

URL

https://shelly.kpfu.ru/e-ksu/docs/F_1170562446/RSC_Advances_2021.pdf

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=246351&p_lang=2

Resource files

File name	Size (MB)	Format
Musashi2_prognostic_biomarker.pdf	1,43	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Bumber Yanis Alekseevich	ru_RU
dc.contributor.author	Deneka Aleksandr Yaroslavovich	ru_RU
dc.contributor.author	Serebriyskiy Ilya Genrikhovich	ru_RU
dc.contributor.author	Tikhomirova Mariya Vladimirovna	ru_RU
dc.contributor.author	Topchu Yuliya Alekseevna	ru_RU
dc.contributor.author	Yugay Veronika Nikolaevna	ru_RU
dc.contributor.author	Ratner Ekaterina Yurevna	ru_RU
dc.contributor.author	Mazitova Aleksandra Maratovna	ru_RU
dc.date.accessioned	2021-01-01T00:00:00Z	ru_RU
dc.date.available	2021-01-01T00:00:00Z	ru_RU
dc.date.issued	2021	ru_RU
dc.identifier.citation	Deneka A. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) /A. Deneka, I.Topchu, N. Karnaukhov, A. Mazitova, V. Yugai, M. Voloshin, M. Tikhomirova, O. Kit, E. Frantsiyants , L.Kharin, T. Airapetova, E. Ratner, Al. Sabirov, Z. Abramova, I. Serebriiskii, Y. Boumber // Journal of Thoracic Disease.-2021.- V.13,N.3.- �. 1370-1379 DOI: 10.1039/d0ra10610k (Q2 SJE 0.572 IF 2.046)	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=246351&p_lang=2	ru_RU
dc.description.abstract	JOURNAL OF THORACIC DISEASE	ru_RU
dc.description.abstract	Background: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). Methods: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received tandard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). Results: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. Conclusions: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	Non-small cell lung cancer (NSCLC)	ru_RU
dc.subject	overall survival (OS)	ru_RU
dc.subject	RNA binding proteins	ru_RU
dc.subject	Musashi-2 (MSI2)	ru_RU
dc.subject	prediction biomarkers	ru_RU
dc.title	Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)	ru_RU
dc.type	Articles in international journals and collections	ru_RU